From innovation to therapeutic care
Go faster for Sickle Cell Disease patients



A based-Genopole company founded on breakthrough innovation, 

INNOVHEM is developing solutions that will both promote the development and optimization of use of treatments for the most common genetic disease over the world, sickle cell disease.


Our proposition

Specific Biomarkers

We are developing specific biomarkers for Red Blood Cell diseases that will improve the development of effective treatments and accompany these treatments in patients to optimize their care.

 Fetal Hemoglobin per Red Blood Cell

- Related to the pathophysilogy of Sickle Cell Disease
- Accurate

A new method to dose intra-vascular hemolysis

- Direct

- Accurate


The Team

A leadership on Sickle Cell Disease

Marie Cambot

Laura Bencheikh

Project Manager


©2019 by INNOVHEM. Proudly created with Wix.com

This site was designed with the
website builder. Create your website today.
Start Now